AARTIPHARM vs WANBURY: Stock Comparison

Aarti Pharmalabs Limited vs Wanbury Ltd

Live data: 22 July 2026, 3:06 PM IST • Source: NSE and company filings

Aarti Pharmalabs Limited is the larger company by market capitalisation. Aarti Pharmalabs Limited shows a higher dividend yield, faster revenue growth and lower leverage, while Wanbury Ltd shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarti Pharmalabs Limited and Wanbury Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AARTIPHARM is more favourable on 6 of 13 scored metrics and WANBURY on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
AARTIPHARM is the larger company
₹6,133 Cr vs ₹1,143 Cr
P/E Ratio
WANBURY has a lower P/E
0x vs 36.57x
P/B Ratio
WANBURY has a lower P/B
0x vs 3.01x
EPS
AARTIPHARM has higher earnings per share
₹19.26 vs ₹13.1
Dividend Yield
AARTIPHARM has a higher dividend yield
0.57% vs 0%
Revenue Growth (TTM YoY)
AARTIPHARM has faster revenue growth
3.3% vs -19.2%
EPS Growth (TTM YoY)
WANBURY has faster EPS growth
0% vs -30.8%
Qtr Sales Growth
WANBURY has stronger quarterly sales growth
24.5% vs 3.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIPHARMWANBURY
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIPHARMWANBURY
Live Price₹674.45₹327.75
Day Change-3.97%-3.15%
Volume1.82 L4.37 L
52-Week High₹969.5₹358.85
52-Week Low₹585₹161.5
Distance from 52W High-30.43%-8.67%

Valuation

MetricAARTIPHARMWANBURY
Market Cap₹6,133 Cr₹1,143 Cr
P/E Ratio36.57x0x
P/B Ratio3.01x0x
EPS₹19.26₹13.1
Book Value₹234.28₹18.1
Dividend Yield0.57%0%

Growth

MetricAARTIPHARMWANBURY
Revenue Growth (TTM YoY)3.3%-19.2%
EPS Growth (TTM YoY)-30.8%0%
Qtr Sales Growth3.35%24.5%
Qtr Profit Growth-30.8%1,197%

Profitability & Leverage

MetricAARTIPHARMWANBURY
ROE8.59%76.5%
ROCE10.7%36.6%
Net Margin10.25%10.17%
Operating Margin20.3%14%
Debt to Equity0.36x3.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIPHARMWANBURY
Promoter Holding42.69% 0.22 pp34.36%
FII Holding8.17% 0.22 pp0.89% 0.3 pp
DII Holding7.22% 0.19 pp0.06% 0.06 pp
Public Holding41.74% 0.63 pp56.03% 0.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarti Pharmalabs Limited and Wanbury Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.